PBIO Stock Overview
Develops and sells high pressure technology-based instruments, consumables, and services for life sciences and other industries worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Pressure BioSciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0045 |
| 52 Week High | US$0.50 |
| 52 Week Low | US$0.0005 |
| Beta | -0.13 |
| 11 Month Change | 80.00% |
| 3 Month Change | -82.00% |
| 1 Year Change | -99.10% |
| 33 Year Change | -99.81% |
| 5 Year Change | -99.44% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| PBIO | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0% | 1.9% | 0.5% |
| 1Y | -99.1% | 3.3% | 30.7% |
Return vs Industry: PBIO underperformed the US Life Sciences industry which returned 3.3% over the past year.
Return vs Market: PBIO underperformed the US Market which returned 30.7% over the past year.
Price Volatility
| PBIO volatility | |
|---|---|
| PBIO Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 8.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PBIO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine PBIO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 16 | Richard Schumacher | www.pressurebiosciences.com |
Pressure BioSciences, Inc. develops and sells high pressure technology-based instruments, consumables, and services for life sciences and other industries worldwide. The company’s products/services are based on Ultra Shear Technology platform, which turns hydrophobic oil-based supplements, therapeutics, and other active ingredients to water-soluble, bioavailable, oil-in-water nano emulsion formulations; BaroFold Technology platform, that is used to improve the quality and lower the production costs of protein biotherapeutics; and Pressure Cycling Technology platform which uses alternating cycles of hydrostatic pressure between ambient and ultra-high pressures to control bio-molecular interactions in sample preparation. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB440, Barocycler HUB880, and the Shredder SG3; Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, and PCT-Micro Pestle; UltraShear Mini, UltraShear K45, and UltraShear Max; and application specific kits, as well as consumable products.
Pressure BioSciences, Inc. Fundamentals Summary
| PBIO fundamental statistics | |
|---|---|
| Market cap | US$184.35k |
| Earnings (TTM) | -US$36.62m |
| Revenue (TTM) | US$1.59m |
0.1x
P/S Ratio0.0x
P/E RatioIs PBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PBIO income statement (TTM) | |
|---|---|
| Revenue | US$1.59m |
| Cost of Revenue | US$1.05m |
| Gross Profit | US$533.54k |
| Other Expenses | US$37.15m |
| Earnings | -US$36.62m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.89 |
| Gross Margin | 33.63% |
| Net Profit Margin | -2,308.30% |
| Debt/Equity Ratio | -69.5% |
How did PBIO perform over the long term?
See historical performance and comparison